BRISTOL-MYERS SQUIBB RECEIVES USE PATENT FOR "UNPATENTABLE" TAXOL: THREE-HOUR BREAST AND OVARIAN INFUSION SCHEDULE COVERED BY PATENT THAT EXPIRES IN 2012

The three-hour infusion schedule for Bristol-Myers Squibb's Taxol (paclitaxel) in breast and ovarian cancer is protected by a newly issued patent that runs through 2012.